| 0 (0%) | 02-21 20:22 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.99 | 1-year : | 13.92 |
| Resists | First : | 11.12 | Second : | 11.92 |
| Pivot price | 10.86  |
|||
| Supports | First : | 9.84 | Second : | 8.18 |
| MAs | MA(5) : | 10.38 |
MA(20) : | 10.76 |
| MA(100) : | 11.28 |
MA(250) : | 8.49 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 26.7 |
D(3) : | 20.5 |
| RSI | RSI(14): 46.3 |
|||
| 52-week | High : | 14.39 | Low : | 4.09 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TRVI ] has closed above bottom band by 36.8%. Bollinger Bands are 21.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.97 - 11.01 | 11.01 - 11.06 |
| Low: | 10.25 - 10.29 | 10.29 - 10.34 |
| Close: | 10.57 - 10.64 | 10.64 - 10.72 |
Sat, 21 Feb 2026
Discipline and Rules-Based Execution in TRVI Response - Stock Traders Daily
Tue, 17 Feb 2026
Trevi Therapeutics Executives to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference - Quiver Quantitative
Tue, 17 Feb 2026
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Globe and Mail
Mon, 16 Feb 2026
Trend Tracker for (TRVI) (TRVI:CA) - Stock Traders Daily
Tue, 10 Feb 2026
Behavioral Patterns of TRVI and Institutional Flows - Stock Traders Daily
Sun, 11 Jan 2026
Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 128 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 105.4 (%) |
| Shares Short | 15,560 (K) |
| Shares Short P.Month | 13,650 (K) |
| EPS | -0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24 % |
| Return on Equity (ttm) | -36.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -44 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -29.56 |
| PEG Ratio | 0 |
| Price to Book value | 7.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -31.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|